GSK Exercises Option for Ionis’ Hepatitis B Programmes

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 9 (Table of Contents)

Published: 3 Sep-2019

DOI: 10.3833/pdr.v2019.i9.2453     ISSN: 1756-7874

Section: Licensing



As it faces generic competition for its respiratory blockbuster Advair (fluticasone propionate/salmeterol), GlaxoSmithKline (GSK) has looked to Ionis Pharmaceuticals for its next revenue source by exercising its option to license two of its antisense therapies, IONIS-HBVRx and IONIS-HBV-LRx, for the treatment of chronic hepatitis B virus infection...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details